2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3084

The Impact of Mental Health on Indicators of Disease Severity Among Patients with Inflammatory Arthritis: A Cross-Sectional and Longitudinal Investigation
Abstract Number: 3054

The Impact of Obesity on Knee Osteoarthritis Symptoms and Related Biomarker Profiles in a Bariatric Surgery Cohort
Abstract Number: 3171

The Impact of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases
Abstract Number: 17

The Importance of Achieving Clinical Response to Treatment and Changes in Physical Ability and Quality of Life on Worker Productivity Outcomes in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register
Abstract Number: 1427

The Importance of Outcome Measures in Ankylosing Spondylitis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Cohort
Abstract Number: 540

The Importance of Outcome Measures in Rheumatoid Arthritis – Validity of the Routine Assessment of Patient Index Data 3 in a Real World Setting
Abstract Number: 2346

The Improving Motivation for Physical Activity in Arthritis Clinical Trial for Adults with Knee Osteoarthritis and Rheumatoid Arthritis
Abstract Number: 2900

The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey
Abstract Number: 1501

The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Abstract Number: 1309

The Incidence of Sexually Acquired Reactive Arthritis: A Systematic Literature Review
Abstract Number: 2296

The Influence of Androgen Deprivation Therapy on Serum Uric Acid Level
Abstract Number: 395

The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Abstract Number: 2272

The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide
Abstract Number: 447

The Influence of Risk Presentation Format on Willingness to Start a Medication
Abstract Number: 3150

The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].